Articles by Lung Cancers Today Editors
The ALA and its LUNG FORCE initiative are lighting up buildings and landmarks across the nation this week to inspire action.
Dr. Le Marchand’s "seminal work has elucidated racial and ethnic disparities in lung cancer risk," officials said.
Dr. Shaw is being recognized for her "groundbreaking work in defining ALK- and ROS1-positive lung cancers," officials said.
Rilvegostomig showed a favorable safety profile and encouraging preliminary efficacy in NSCLC.
Rilertinib showed significantly longer progression-free survival compared with gefitinib.
Plinabulin combined with docetaxel showed improved survival in patients with wild-type EGFR NSCLC.
Osimertinib demonstrated a manageable safety profile for the treatment of stage III EGFR-mutated NSCLC.
More than one-third of patients with platinum-resistant ES-SCLC responded to treatment.
A personalized music therapy regimen also mediated postoperative dyspnea symptoms.
HR20013 was noninferior to fosaprepitant plus palonesetron at reducing nausea related to cisplatin-based chemotherapy.
Nivolumab with or without relatlimab demonstrated promising survival rates at 2 years postoperatively.
Novocure will examine TTFields at the conference, placing particular emphasis on a post-hoc analysis using data from LUNAR.
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.